McKesson Settles 2018 Price Fixing Suit With $141m Payment
Class Of Shareholders Had Alleged Financials ‘Premised On Illegal Activity’
Executive Summary
US distribution giant McKesson has reached a nine-figure settlement deal with shareholders to resolve a class action lawsuit alleging that it participated in a price-fixing and anticompetitive scheme for generic drugs with manufacturers and other wholesalers.
You may also be interested in...
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
McKesson shuffles pack
US-based wholesaler and retailer McKesson Corporation is to promote president and chief operating officer Brian Tyler to the role of chief executive officer following the retirement of John Hammergren.
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.